Brief: HilleVax Announces Completion Of Enrollment Of NEST-IN1 Phase 2b Clinical Study Of HIL-214 Norovirus Vaccine Candidate
25/04/2023 14:04
April 25 (Reuters) - Hillevax Inc HLVX.O :
* HILLEVAX ANNOUNCES COMPLETION OF ENROLLMENT OF NEST-IN1
PHASE 2B
CLINICAL STUDY OF HIL-214 NOROVIRUS VACCINE CANDIDATE
* HILLEVAX INC - TOPLINE SAFETY AND CLINICAL EFFICACY DATA
FROM
NEST-IN1 ARE EXPECTED IN Q1 OF 2024
Source text for Eikon: ID:nGNX5Z0g04
Further company coverage: HLVX.O
Recent news on HilleVax
See all newsBrief: XOMA Royalty Announces Closing Of Tender Offer For HilleVax
Brief: Hillevax Enters Into A Definitive Agreement To Be Acquired By Xoma Royalty For $1.95 In Cash Per Share Plus A Contingent Value Right
U.S. STOCKS ON THE MOVE-US energy sector, Oshkosh, Meta
U.S. STOCKS ON THE MOVE-Zumiez, BTC Digital, WesBanco
U.S. STOCKS ON THE MOVE-Petco Health, Smith & Wesson, Victoria's Secret